Valuation: Pfizer

Market Cap 139B 121B 112B 104B 197B 13,221B 199B 1,332B 519B 6,487B 520B 509B 22,463B P/E 2026 *
11.5x
P/E 2027 * 12x
Enterprise Value 188B 164B 151B 140B 267B 17,909B 270B 1,804B 703B 8,787B 705B 690B 30,430B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 3.06x
Free-Float
59.06%
Yield 2026 *
7.38%
Yield 2027 * 7.35%
Manager TitleAgeSince
Chief Executive Officer 64 2018-12-31
Director of Finance/CFO 60 2022-05-01
Chief Tech/Sci/R&D Officer - 2006-12-31
Director TitleAgeSince
Director/Board Member 68 2007-08-31
Director/Board Member 62 2013-09-26
Chairman 64 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 139B
-1.14%-0.67%+53.72%+157.69% 1,082B
-1.41%+1.83%+66.23%+59.28% 633B
-2.42%+0.56%+34.59%+85.12% 461B
-0.26%+1.37%+31.00%+23.05% 338B
-2.46%-1.52%+36.42%+32.77% 299B
-2.20%-0.93%+27.50%+40.62% 291B
-1.77%+0.99%-28.85%-41.41% 222B
-2.06%+2.26%+22.87%+62.23% 202B
-1.26%+1.35%+15.98%+67.80% 163B
Average -0.88%+4.45%+28.83%+54.13% 410.27B
Weighted average by Cap. -0.40%+5.43%+39.61%+78.91%

Financials

2026 *2027 *
Net sales 61.71B 53.92B 49.68B 46.08B 87.66B 5,886B 88.7B 593B 231B 2,888B 232B 227B 10,000B 59.34B 51.85B 47.77B 44.31B 84.29B 5,660B 85.3B 570B 222B 2,777B 223B 218B 9,617B
Net income 11.07B 9.67B 8.91B 8.27B 15.73B 1,056B 15.91B 106B 41.45B 518B 41.57B 40.66B 1,794B 10.72B 9.36B 8.63B 8B 15.22B 1,022B 15.4B 103B 40.12B 502B 40.24B 39.36B 1,737B
Net Debt 49.16B 42.96B 39.58B 36.71B 69.83B 4,689B 70.66B 472B 184B 2,301B 185B 181B 7,967B 42.94B 37.53B 34.57B 32.07B 61B 4,096B 61.73B 413B 161B 2,010B 161B 158B 6,959B
Logo Pfizer
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
24.32USD
Average target price
29.00USD
Spread / Average Target
+19.25%

Quarterly revenue - Rate of surprise